- Home
- OAKU vs DTIL Comparison
OAKU vs DTIL Comparison
Compare OAKU & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OAKU
- DTIL
- Stock Information
- Founded
- OAKU 2022
- DTIL 2006
- Country
- OAKU Canada
- DTIL United States
- Employees
- OAKU N/A
- DTIL N/A
- Industry
- OAKU Blank Checks
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- OAKU Finance
- DTIL Health Care
- Exchange
- OAKU Nasdaq
- DTIL Nasdaq
- Market Cap
- OAKU 62.7M
- DTIL 51.6M
- IPO Year
- OAKU 2023
- DTIL 2019
- Fundamental
- Price
- OAKU $11.70
- DTIL $4.15
- Analyst Decision
- OAKU
- DTIL Strong Buy
- Analyst Count
- OAKU 0
- DTIL 2
- Target Price
- OAKU N/A
- DTIL $47.00
- AVG Volume (30 Days)
- OAKU 161.0
- DTIL 531.7K
- Earning Date
- OAKU 01-01-0001
- DTIL 07-31-2025
- Dividend Yield
- OAKU N/A
- DTIL N/A
- EPS Growth
- OAKU N/A
- DTIL N/A
- EPS
- OAKU 0.03
- DTIL N/A
- Revenue
- OAKU N/A
- DTIL $51,141,000.00
- Revenue This Year
- OAKU N/A
- DTIL N/A
- Revenue Next Year
- OAKU N/A
- DTIL $30.20
- P/E Ratio
- OAKU $312.34
- DTIL N/A
- Revenue Growth
- OAKU N/A
- DTIL N/A
- 52 Week Low
- OAKU $10.88
- DTIL $3.61
- 52 Week High
- OAKU $12.02
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- OAKU 26.75
- DTIL 36.07
- Support Level
- OAKU $11.70
- DTIL $4.08
- Resistance Level
- OAKU $11.71
- DTIL $4.38
- Average True Range (ATR)
- OAKU 0.00
- DTIL 0.32
- MACD
- OAKU -0.01
- DTIL -0.08
- Stochastic Oscillator
- OAKU 0.00
- DTIL 10.24
About OAKU Oak Woods Acquisition Corporation
Oak Woods Acquisition Corp is a a newly-incorporated blank check company. It is formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more target businesses.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.